We report a case of a 54-year-old woman who received anthracycline (idarubicin, accumulated dose 400 mg/m<sup>2</sup> doxorubicin equivalent) for her acute promyelocytic leukocyte 10 years ago, had no relevant comorbidities or other pre-existing cardiovascular diseases, had maintained normal cardiac function, presenting with new-onset dyspnea at rest and bilateral lower extremities swelling 12 weeks after receiving trastuzumab induction chemotherapy for her newly diagnosed early stage HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.